CALR and colonic neoplasm: The knockdown of CRT by specific siRNA or its blockade by specific antibody compromised the immunogenicity of mitoxantrone-treated CT26 mouse colon cancer cells, which was restored when recombinant CRT was used to compensate for the CRT defect.